NR1I2
Nuclear receptor subfamily 1 group I member 2
Also known as: BXR, NR1I2_HUMAN, ONR1, PAR2, PXR, SXR
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O75469
- Gene
- NR1I2
- Ensembl
- ENSG00000144852
- Chromosome
- 3
- Canonical length
- 434 aa
- Protein class
- FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors, Transporters
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
This gene product belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. The encoded protein is a transcriptional regulator of the cytochrome P450 gene CYP3A4, binding to the response element of the CYP3A4 promoter as a heterodimer with the 9-cis retinoic acid receptor RXR. It is activated by a range of compounds that induce CYP3A4, including dexamethasone and rifampicin. Several alternatively spliced transcripts encoding different isoforms, some of which use non-AUG (CUG) translation initiation codon, have been described for this gene. Additional transcript variants exist, however, they have not been fully characterized. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
434 residues, UniProt reviewed canonical sequence.
>O75469|NR1I2
1 MEVRPKESWN HADFVHCEDT ESVPGKPSVN ADEEVGGPQI CRVCGDKATG YHFNVMTCEG
61 CKGFFRRAMK RNARLRCPFR KGACEITRKT RRQCQACRLR KCLESGMKKE MIMSDEAVEE
121 RRALIKRKKS ERTGTQPLGV QGLTEEQRMM IRELMDAQMK TFDTTFSHFK NFRLPGVLSS
181 GCELPESLQA PSREEAAKWS QVRKDLCSLK VSLQLRGEDG SVWNYKPPAD SGGKEIFSLL
241 PHMADMSTYM FKGIISFAKV ISYFRDLPIE DQISLLKGAA FELCQLRFNT VFNAETGTWE
301 CGRLSYCLED TAGGFQQLLL EPMLKFHYML KKLQLHEEEY VLMQAISLFS PDRPGVLQHR
361 VVDQLQEQFA ITLKSYIECN RPQPAHRFLF LKIMAMLTEL RSINAQHTQR LLRIQDIHPF
421 ATPLMQELFG ITGSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NR1I2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.35
- Highest tissue expression
- 44 nTPM
Expression across tissuesHPA
Tissue
- liver: 44 nTPM
- small intestine: 29 nTPM
- duodenum: 27 nTPM
- rectum: 13 nTPM
- colon: 12 nTPM
- gallbladder: 4.9 nTPM
Single-cell type
- enterocytes: 61 nCPM
- hepatocytes: 40 nCPM
- colonocytes: 27 nCPM
- enteric transient amplifying cells: 16 nCPM
- enteric stem cells: 14 nCPM
- paneth cells: 12 nCPM
Immune cell
- NK-cell: 2.9 nTPM
- T-reg: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- hypothalamus: 0.8 nTPM
- midbrain: 0.7 nTPM
- pons: 0.6 nTPM
- basal ganglia: 0.5 nTPM
- choroid plexus: 0.5 nTPM
- medulla oblongata: 0.5 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.17
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.62
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell differentiation
- cellular response to molecule of bacterial origin
- gene expression
- intestinal epithelial structure maintenance
- intracellular receptor signaling pathway
- negative regulation of DNA-templated transcription
- negative regulation of transcription by RNA polymerase II
- positive regulation of DNA-templated transcription
- positive regulation of gene expression
- positive regulation of transcription by RNA polymerase II
- regulation of DNA-templated transcription
- signal transduction
- steroid metabolic process
- xenobiotic catabolic process
- xenobiotic metabolic process
- xenobiotic transport
Molecular functions
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity, RNA polymerase II-specific
- nuclear receptor activity
- nuclear receptor binding
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Nuclear hormone receptor, ligand-binding domain
- Zinc finger, nuclear hormone receptor-type
- Nuclear hormone receptor
- Zinc finger, NHR/GATA-type
- Nuclear hormone receptor-like domain superfamily
- Nuclear hormone receptor family NR1 subfamily
- Ligand-binding domain of nuclear hormone receptor
- Double treble clef zinc finger, C4 type
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NR1I2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NR1I2 as an antibody target. Whether an autoantibody or antibody against NR1I2 could matter depends on whether native NR1I2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NR1I2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NR1I2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...